MedTrace Logo

Treatment of Extended Spectrum Betalactamase Producing Bacteria Causing Urinary Tract Infections in General Practice

NCT01531023 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 168

Last updated 2016-10-31

No results posted yet for this study

Summary

The prevalence of extended spectrum beta-lactamase (ESBL) producing bacteria found in urine sample cultures has been increasing over the past decades.

The study hypothesis is to assess the clinical and microbiological outcome of pivmecillinam treatment of ESBL producing E. coli and K. Pneumoni, as well as to observe the clinical and microbiological outcome of the same group of bacteria treated with other antiinfectious agents.

Samples are gathered in primary care setting.

Conditions

Sponsors & Collaborators

  • University Hospital of North Norway

    collaborator OTHER

  • St. Olavs Hospital

    collaborator OTHER

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • The Hospital of Vestfold

    collaborator OTHER

  • Vestre Viken Hospital Trust

    collaborator OTHER

  • University Hospital, Akershus

    collaborator OTHER

  • Unilabs

    collaborator UNKNOWN

  • University of Oslo

    lead OTHER

Principal Investigators

  • Morten Lindbaek, Md PhD · University of Oslo

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01531023 on ClinicalTrials.gov